Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?

The treatment of hormone receptor-positive, HER2-negative breast cancer has become increasingly individualized, thanks to the development of genomic testing. Gene expression assays provide clinicians and patients with both prognostic and predictive information regarding breast cancer recurrence risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Caitlin, Meisel, Jane, Kalinsky, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958684/
https://www.ncbi.nlm.nih.gov/pubmed/35356261
http://dx.doi.org/10.1177/17588359221084769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958684/
https://www.ncbi.nlm.nih.gov/pubmed/35356261
http://dx.doi.org/10.1177/17588359221084769

Ejemplares similares